Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy.

@article{Richey2011OutcomeOP,
  title={Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy.},
  author={Stephen Lane Richey and Stephen H. Culp and Eric Jonasch and Paul G. Corn and Lance C. Pagliaro and Pheroze Tamboli and Kazoomi K Patel and Surena F Matin and Christopher G Wood and Nizar M. Tannir},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2011},
  volume={22 5},
  pages={
          1048-53
        }
}
BACKGROUND Cytoreductive nephrectomy (CN) became a standard procedure in metastatic renal cell carcinoma (mRCC) in the immunotherapy era. Historically, median overall survival (OS) of patients treated with interferon alpha (IFN-α) without CN was 7.8 months. Median OS in patients treated with targeted therapy (TT) without CN is unknown. PATIENTS AND METHODS We retrospectively reviewed records of patients with mRCC who received TT without CN. Kaplan-Meier methods and Cox regression analysis… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 33 CITATIONS

CBFA2T2 is associated with a cancer stem cell state in renal cell carcinoma

  • Cancer Cell International
  • 2017
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 31 REFERENCES

Similar Papers

Loading similar papers…